Drug Profile
Epetraborole - Pfizer
Alternative Names: AN-3365; AN2-501971; BRII-658; GSK '052; GSK-052; GSK-2251052Latest Information Update: 22 Feb 2024
Price :
$50
*
At a glance
- Originator Anacor Pharmaceuticals
- Developer AN2 Therapeutics; Anacor Pharmaceuticals; GlaxoSmithKline
- Class 2 ring heterocyclic compounds; Anti-infectives; Antibacterials; Benzene derivatives; Organic boron compounds; Small molecules
- Mechanism of Action Leucyl-tRNA synthetase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Nontuberculous mycobacterium infections
- Preclinical Melioidosis
- Suspended Gram-negative infections
- Discontinued Intra-abdominal infections; Urinary tract infections
Most Recent Events
- 13 Feb 2024 AN2 Therapeutics pause enrolment in a phase III part of phase II/III trial for Nontuberculous mycobacterium infections (Treatment-resistant) in USA, Australia, Japan, South Korea (NCT05327803)
- 27 Nov 2023 Antimicrobial data from preclinical studies in Mycobacterium infections presented at the IDWeek-2023 (IDW-2023)
- 11 Oct 2023 Adverse events and pharmacokinetics data from a phase I trial in Nontuberculous mycobacterium infections presented at the IDWeek 2023 (IDW-2023)